According to the immunotherapy trials of HCC in recent years [61], the checkpoint inhibitors of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) engage CD8 immunity [62]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.